FYN and breast cancer: Tamoxifen resistance in breast cancer (ER+) is caused by Fyn, and the proliferation of tamoxifen-resistant cells and the correlation of tamoxifen-resistant cells with a poor prognosis in breast cancer are markedly decreased by the use of a Fyn inhibitor or by the knockdown of Fyn expression (Joshi et al., 2016).